PrognomiQ, a healthcare company focused on harnessing the power of proteomics and multi-omics data to transform the detection and early treatment selection and monitoring of cancer, today announced ...
Scientists, funded by Cancer Research UK, have now passed another hurdle, bringing the test closer to patient use ...
About half of people diagnosed with metastatic non-small-cell lung cancer don't receive systemic therapies, pointing to ...
The study, published in the International Journal of Molecular Science, focused on Non-Small Cell Lung Cancer, the most common form of the disease, accounting for roughly 80 to 85 percent of all lung ...
For nearly half of people diagnosed with lung cancer, immunotherapy can slow the disease but not stop it. Funded through a $4 million joint investment from the Canadian Cancer Society (CCS) and the ...
(Nanowerk News) In a major step forward for cancer care, researchers at ChristianaCare’s Gene Editing Institute have shown that disabling the NRF2 gene with CRISPR technology can reverse chemotherapy ...
Roche Pharma India has launched a subcutaneous Tecentriq injection for eligible lung cancer patients. The shorter dosing time ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The five-year survival rate for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results